Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU

Executive Summary

The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.

You may also be interested in...



EU Marketing Decisions For New Drugs Imminent For Sanofi, PTC, Calliditas & Others

The European Medicines Agency’s human medicines committee, the CHMP, is expected to decide whether 11 drugs should be recommended for marketing approval during its latest monthly meeting, which started today.

New EU Filings

Vutrisiran, Alnylam’s investigational RNAi therapeutic for treating hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy, is among the latest new medicines that have been submitted for review for potential pan-EU approval.

New EU Filings

Asciminib, Novartis's drug for patients with chronic myeloid leukemia, is among the latest new medicines that have been submitted for pan-EU approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS144785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel